A couple of weeks ago I wrote about a remarkable study, just published in the BMJ which had found that over half of the new cancer drugs released onto the market in a four year period by the EU drugs regulator had no good evidence that they were effective. In other words, there was also no evidence that their benefits outweighed their risk or that they were value for money.

The public news about cancer […]